加巴喷丁类药物与脊髓电刺激较低取出率相关:203例FBSS患者研究
本研究纳入1997年1月至2014年3月单中心连续203例因腰椎术后失败综合征(FBSS)接受脊髓电刺激(SCS)的患者,结合1995年1月至2016年3月全国登记处药物购买数据分析加巴喷丁类药物对SCS结局的影响。
要点
- 使用加巴喷丁类药物与SCS 2年取出率显著降低相关(HR 0.2)。
- 植入前阿片剂量>40吗啡毫克当量者取出风险显著升高(HR 6.7)。
- 加巴喷丁类药物使用者更常停用阿片或将剂量减少>50%(OR 5.7)。
核心结论
- 使用加巴喷丁类药物与脊髓电刺激器取出率显著降低及停用阿片或剂量减少>50%机会更高相关,提示SCS患者可能受益于联用加巴喷丁类药物,但需前瞻性随机试验验证。
研究设计与样本
- 单中心回顾性队列研究,纳入1997年1月至2014年3月连续203例接受SCS的FBSS患者,并从全国登记处获取1995年1月至2016年3月药物购买数据。
临床怎么用
- 对拟行或已行SCS的FBSS患者,可关注加巴喷丁类药物的联用及其与阿片减量的关系。
- 植入前阿片剂量>40吗啡毫克当量者取出风险较高,术前应加强评估与镇痛管理。
局限性
- 为单中心回顾性队列研究,样本来自1997至2014年,结论需前瞻性随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). The effect of neuropathic pain medication use on SCS outcome is poorly understood. OBJECTIVE: To study the effect of gabapentinoid use on SCS outcome measured by trial success, explantation rate and opioid dose reduction during a 2-yr follow-up. METHODS: The study cohort included 203 consecutive FBSS patients who underwent SCS in a single tertiary center during January 1997 to March 2014. Purchase data of gabapentinoids, opioids, tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors, and benzodiazepines during January 1995 to March 2016 were retrieved from national registries. RESULTS: In multivariate Cox regression analysis, patients using gabapentinoids had significantly fewer explantations during the 2-yr follow-up (hazard ratio [HR] 0.2, 95% CI 0.04-0.81, P = .03). In contrast, patients with opioid use of >40 morphine milligram equivalent before implantation had significantly more explantations (HR 6.7, 95% CI 2.5-18, P < .01). In bivariate logistic regression analysis adjusted for patient specific factors, year of SCS implantation, use of neuropathic pain medication, opioids, and benzodiazepines, patients using gabapentinoids significantly more often discontinued opioids or reduced their dose by more than 50% during the 2-yr follow-up (odds ratio 5.7, 95% CI 1.4-23, P = .015). CONCLUSION: The use of gabapentinoids was associated with a significantly lower spinal cord stimulator explantation rate and a higher chance of opioid discontinuation or >50% dose reduction. This indicates that patients with SCS could benefit from concomitant use of gabapentinoids. Prospective randomized trials are warranted to verify this hypothesis.
引用
- Nissen M, Ikäheimo TM, Huttunen J, et al. Gabapentinoids Associated With Lower Explantation Rate in 203 Patients With Spinal Cord Stimulation for Failed Back Surgery Syndrome. Neurosurgery. 2021. PMID: 34270731. doi:10.1093/neuros/nyab242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。